Short answer
Biohaven Ltd. (BHVN) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 contains only an incorporation-by-reference disclaimer.
Biohaven Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only an incorporation-by-reference disclaimer
- No operating results, financial figures, or fiscal-year 2026 performance data provided
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss $130.5M, or $0.88 per share, versus $221.7M, or $2.17, reflecting sharply lower operating expenses
- R&D expense fell to $103.8M from $187.6M following strategic program reprioritization, improving cash preservation but narrowing development investment
- Cash, marketable securities and restricted cash totaled approximately $351.8M at March 31, 2026, against $241.9M in notes payable
- Key 2026 catalysts include opakalim epilepsy results and taldefgrobep obesity data in 2H 2026
- BHV-1400 IgAN and BHV-1300 Graves’ disease pivotal trials expected to begin by mid-year 2026, advancing Biohaven’s degrader platforms toward late-stage validation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biohaven Ltd. 8-K filings
Get the next BHVN 8-K as it lands
Follow BHVN for push alerts, or ask the research agent what this filing means.